Siirry pääsisältöön
Käyttämääsi selainta ei enää tueta – lue lisää.

Bavarian Nordic

Ylin-
Alin-
Vaihto-
2026 Q1 -tulosraportti
75 päivää sitten

Tarjoustasot

Ei dataa

Viimeisimmät kaupat

AikaHintaMääräOstajaMyyjä
----

Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.

Välittäjätilasto

Dataa ei löytynyt

Yhtiötapahtumat

Datan lähde: FactSet, Quartr
Seuraava tapahtuma
2026 Q2 -tulosraportti
21.8.
Menneet tapahtumat
2026 Q1 -tulosraportti
13.5.
2025 Q4 -tulosraportti
12.3.
2025 Q3 -tulosraportti
14.11.2025
2025 Q2 -tulosraportti
22.8.2025
2025 Q1 -tulosraportti
9.5.2025

Foorumi

Liity keskusteluun Nordnet Socialissa
Kirjaudu
  • 1 t sitten · Muokattu
    ·
    I understand that technical analysis points a bit to what my daughter would call "lame" in the short term (not that I myself am a big expert in technical analysis). Despite this, I am still close to buying BAVA again for her more long-term portfolio. I have on many occasions had success with large gains in this stock. And I think it is now being beaten down to the bottom again. My considerations are, as those who are in BAVA know well; a) geopolitical unrest provides stable future earnings on mpox, and occasional boosts from mpox outbreaks, and b) the travel vaccines that BAVA bought in 2019/20 seem to be growing steadily in earnings - and relatively good economic key figures in the USA will surely mean more travelers etc etc (even though jet fuel is naturally a negative factor at present). I understand that several experts see a potential of 3-4 billion annually for the chikungunya vaccine (and the only competitor is the small flimsy French company with bad side effects). If this is correctly assumed, and the vaccine is not even rolled out in e.g. Brazil - then we are surely looking forward to a "blue ocean" scenario? I just can't really figure out what "bulk-vaccine-demand" there is at a governmental level in South and Latin America etc - does anyone have knowledge about this? Could Bill Gates not also consider expanding his philanthropic vaccine program to developing countries with this vaccine? (However, I am not familiar with the selection criteria for this program?) In addition, there is probably a possibility for yet another acquisition scenario (where I fortunately sold last time).
  • 2 päivää sitten
    ·
    Bavarinn currently has a market capitalization of 14 Mia, and an equity of approx. 13 Mia. I believe Bavarian owns approx 4% of the shares. Does anyone know why Bavarian has chosen to have such a large cash holding? If the money is not to be used to grow the company, they can buy back their own shares. This would stop the bleeding for us shareholders. Does anyone know when Chaplin stops.
    2 päivää sitten
    ·
    13 billion is a lot of money, is there a plan
  • 2 päivää sitten
    ·
    Hasn't ATP noticed the fall? When 250 was too cheap, why haven't they supplemented at this level?
    2 päivää sitten
    ·
    Yes, but look what they have done in Novo, and by buying a bit more at this level, and thereby lowering the average price, it might be possible to get rid of a bit more, because aren't we close to trading it close to its intrinsic value, and how many stocks that have come with an upward revision, are traded at that level.
  • 3 päivää sitten
    ·
    Hopefully, Bavarian will soon buy back its own shares.
    3 päivää sitten
    ·
    Hopeless share price, hopeless company, POOR (no) shareholder care, POOR communication....- crap... I'm stuck with 2000 shares, have loooong been "dead" money.... Hope new CEO can get the company off the ground 🙏🏻😵‍💫
  • 3 päivää sitten
    ·
    What's happening with Bavarian? About 9 months ago it cost almost 250 kr. ATP and many others estimated the price to be even higher, which is why they recommended not selling at 250 kr. And since then (approx. October 2025) it has only gone one way; DOWN. Does anyone have a qualified explanation?
    3 päivää sitten
    ·
    Buy many more when it falls to 150 kr
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, ​​eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.

Uutiset

Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.

Tuotteita joiden kohde-etuutena tämä arvopaperi

2026 Q1 -tulosraportti
75 päivää sitten

Uutiset

Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.

Foorumi

Liity keskusteluun Nordnet Socialissa
Kirjaudu
  • 1 t sitten · Muokattu
    ·
    I understand that technical analysis points a bit to what my daughter would call "lame" in the short term (not that I myself am a big expert in technical analysis). Despite this, I am still close to buying BAVA again for her more long-term portfolio. I have on many occasions had success with large gains in this stock. And I think it is now being beaten down to the bottom again. My considerations are, as those who are in BAVA know well; a) geopolitical unrest provides stable future earnings on mpox, and occasional boosts from mpox outbreaks, and b) the travel vaccines that BAVA bought in 2019/20 seem to be growing steadily in earnings - and relatively good economic key figures in the USA will surely mean more travelers etc etc (even though jet fuel is naturally a negative factor at present). I understand that several experts see a potential of 3-4 billion annually for the chikungunya vaccine (and the only competitor is the small flimsy French company with bad side effects). If this is correctly assumed, and the vaccine is not even rolled out in e.g. Brazil - then we are surely looking forward to a "blue ocean" scenario? I just can't really figure out what "bulk-vaccine-demand" there is at a governmental level in South and Latin America etc - does anyone have knowledge about this? Could Bill Gates not also consider expanding his philanthropic vaccine program to developing countries with this vaccine? (However, I am not familiar with the selection criteria for this program?) In addition, there is probably a possibility for yet another acquisition scenario (where I fortunately sold last time).
  • 2 päivää sitten
    ·
    Bavarinn currently has a market capitalization of 14 Mia, and an equity of approx. 13 Mia. I believe Bavarian owns approx 4% of the shares. Does anyone know why Bavarian has chosen to have such a large cash holding? If the money is not to be used to grow the company, they can buy back their own shares. This would stop the bleeding for us shareholders. Does anyone know when Chaplin stops.
    2 päivää sitten
    ·
    13 billion is a lot of money, is there a plan
  • 2 päivää sitten
    ·
    Hasn't ATP noticed the fall? When 250 was too cheap, why haven't they supplemented at this level?
    2 päivää sitten
    ·
    Yes, but look what they have done in Novo, and by buying a bit more at this level, and thereby lowering the average price, it might be possible to get rid of a bit more, because aren't we close to trading it close to its intrinsic value, and how many stocks that have come with an upward revision, are traded at that level.
  • 3 päivää sitten
    ·
    Hopefully, Bavarian will soon buy back its own shares.
    3 päivää sitten
    ·
    Hopeless share price, hopeless company, POOR (no) shareholder care, POOR communication....- crap... I'm stuck with 2000 shares, have loooong been "dead" money.... Hope new CEO can get the company off the ground 🙏🏻😵‍💫
  • 3 päivää sitten
    ·
    What's happening with Bavarian? About 9 months ago it cost almost 250 kr. ATP and many others estimated the price to be even higher, which is why they recommended not selling at 250 kr. And since then (approx. October 2025) it has only gone one way; DOWN. Does anyone have a qualified explanation?
    3 päivää sitten
    ·
    Buy many more when it falls to 150 kr
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, ​​eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.

Tarjoustasot

Ei dataa

Viimeisimmät kaupat

AikaHintaMääräOstajaMyyjä
----

Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.

Välittäjätilasto

Dataa ei löytynyt

Yhtiötapahtumat

Datan lähde: FactSet, Quartr
Seuraava tapahtuma
2026 Q2 -tulosraportti
21.8.
Menneet tapahtumat
2026 Q1 -tulosraportti
13.5.
2025 Q4 -tulosraportti
12.3.
2025 Q3 -tulosraportti
14.11.2025
2025 Q2 -tulosraportti
22.8.2025
2025 Q1 -tulosraportti
9.5.2025

Tuotteita joiden kohde-etuutena tämä arvopaperi

2026 Q1 -tulosraportti
75 päivää sitten

Uutiset

Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.

Yhtiötapahtumat

Datan lähde: FactSet, Quartr
Seuraava tapahtuma
2026 Q2 -tulosraportti
21.8.
Menneet tapahtumat
2026 Q1 -tulosraportti
13.5.
2025 Q4 -tulosraportti
12.3.
2025 Q3 -tulosraportti
14.11.2025
2025 Q2 -tulosraportti
22.8.2025
2025 Q1 -tulosraportti
9.5.2025

Tuotteita joiden kohde-etuutena tämä arvopaperi

Foorumi

Liity keskusteluun Nordnet Socialissa
Kirjaudu
  • 1 t sitten · Muokattu
    ·
    I understand that technical analysis points a bit to what my daughter would call "lame" in the short term (not that I myself am a big expert in technical analysis). Despite this, I am still close to buying BAVA again for her more long-term portfolio. I have on many occasions had success with large gains in this stock. And I think it is now being beaten down to the bottom again. My considerations are, as those who are in BAVA know well; a) geopolitical unrest provides stable future earnings on mpox, and occasional boosts from mpox outbreaks, and b) the travel vaccines that BAVA bought in 2019/20 seem to be growing steadily in earnings - and relatively good economic key figures in the USA will surely mean more travelers etc etc (even though jet fuel is naturally a negative factor at present). I understand that several experts see a potential of 3-4 billion annually for the chikungunya vaccine (and the only competitor is the small flimsy French company with bad side effects). If this is correctly assumed, and the vaccine is not even rolled out in e.g. Brazil - then we are surely looking forward to a "blue ocean" scenario? I just can't really figure out what "bulk-vaccine-demand" there is at a governmental level in South and Latin America etc - does anyone have knowledge about this? Could Bill Gates not also consider expanding his philanthropic vaccine program to developing countries with this vaccine? (However, I am not familiar with the selection criteria for this program?) In addition, there is probably a possibility for yet another acquisition scenario (where I fortunately sold last time).
  • 2 päivää sitten
    ·
    Bavarinn currently has a market capitalization of 14 Mia, and an equity of approx. 13 Mia. I believe Bavarian owns approx 4% of the shares. Does anyone know why Bavarian has chosen to have such a large cash holding? If the money is not to be used to grow the company, they can buy back their own shares. This would stop the bleeding for us shareholders. Does anyone know when Chaplin stops.
    2 päivää sitten
    ·
    13 billion is a lot of money, is there a plan
  • 2 päivää sitten
    ·
    Hasn't ATP noticed the fall? When 250 was too cheap, why haven't they supplemented at this level?
    2 päivää sitten
    ·
    Yes, but look what they have done in Novo, and by buying a bit more at this level, and thereby lowering the average price, it might be possible to get rid of a bit more, because aren't we close to trading it close to its intrinsic value, and how many stocks that have come with an upward revision, are traded at that level.
  • 3 päivää sitten
    ·
    Hopefully, Bavarian will soon buy back its own shares.
    3 päivää sitten
    ·
    Hopeless share price, hopeless company, POOR (no) shareholder care, POOR communication....- crap... I'm stuck with 2000 shares, have loooong been "dead" money.... Hope new CEO can get the company off the ground 🙏🏻😵‍💫
  • 3 päivää sitten
    ·
    What's happening with Bavarian? About 9 months ago it cost almost 250 kr. ATP and many others estimated the price to be even higher, which is why they recommended not selling at 250 kr. And since then (approx. October 2025) it has only gone one way; DOWN. Does anyone have a qualified explanation?
    3 päivää sitten
    ·
    Buy many more when it falls to 150 kr
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, ​​eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.

Tarjoustasot

Ei dataa

Viimeisimmät kaupat

AikaHintaMääräOstajaMyyjä
----

Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.

Välittäjätilasto

Dataa ei löytynyt